DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI

Information source: University of California, San Francisco
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Traumatic Brain Injury (TBI); Hazardous and Harmful Alcohol Use

Intervention: Medical Management Counseling (Behavioral); Topiramate (Drug); Placebo (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University of California, San Francisco

Official(s) and/or principal investigator(s):
Steven L. Batki, MD, Principal Investigator, Affiliation: University of California, San Francisco

Overall contact:
Brooke A. Lasher, BA, Phone: 415/221-4810, Ext: 4954, Email: brooke.lasher@va.gov

Summary

The goal of the proposed project is to improve the treatment of veterans with co-occurring traumatic brain injury (TBI) and hazardous or harmful alcohol use. The PI and coinvestigators will conduct a pilot controlled clinical trial of topiramate for the treatment of these co-occurring disorders.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Change in the number of drinking days as assessed by the Timeline Followback (TLFB)

Secondary outcome: Change in TBI symptoms as assessed by the Neurobehavioral Symptom Inventory (NSI)

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria 1. Male and female veterans. 2. Ages 18 to 65 (inclusive). 3. TBI: a history of mild traumatic brain injury, as defined by American Congress of Rehabilitation Medicine (ACRM) and VA, in the chronic, stable phase of recovery (>6 months from injury). The ACRM defines mild TBI as a traumatically-induced physiological disruption of brain function as demonstrated by at least one of the following: 3. a. loss of consciousness of up to 30 minutes; 3. b. any loss of memory for events immediately before or after the event; 3. c. any alteration in mental state at the time of the event, for example feeling dazed, disoriented, or confused; and 3. d. a focal neurological deficit or deficits that may or may not have been transient, for example loss of coordination, speech difficulties, or double vision. ACRM's definition further specifies that a person may be designated as having a mild TBI only if the severity of the injury does not include a loss of consciousness that lasted longer than 30 minutes, and post-traumatic amnesia lasting longer than 24 hours. Rationale: 1. This is the most common description of patients currently served by our VA facilities. 2. Studies at this stable phase will facilitate detection of otherwise subtle changes as findings are less likely to be confounded by 'spontaneous' recovery. 4. Current (past month) hazardous alcohol use or harmful alcohol use. 4. a. Hazardous use is drinking that must meet criteria for "at-risk" or "heavy" drinking by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria: Subjects must report current (past 30 day) "at-risk" or "heavy" drinking on an average weekly basis, consisting of an average of 15 or more standard drinks per week for men and 8 or more standard drinks per week for women during the 30 days prior to Screening Visit 1 as measured by the Alcohol Timeline Followback (TLFB) method. 4. b. Harmful use is drinking behavior that meets Diagnostic and Statistical Manual (DSM)-IV diagnostic criteria for an Alcohol Use Disorder (Alcohol Dependence or Alcohol Abuse). 5. Subjects must express a desire to reduce or stop alcohol use. 6. Female subjects must have a negative urine pregnancy test and must be either postmenopausal for at least 1 year or practicing an effective method of birth control (e. g., surgically sterile, spermicide with barrier, male partner sterilization; or absent and agrees to continue abstinence or to use an acceptable method of contraception, as listed above, should sexual activity commence). 7. Subjects must have a Breath Alcohol Concentration (BAC) of less than 0. 02% when signing the informed consent form. Exclusion Criteria 1. Psychotic disorders, bipolar disorders, dementia, or other psychiatric disorders judged to be unstable. 2. Subjects known to have clinically significant unstable medical conditions, including but not limited to: Clinically significant renal disease and/or impaired renal function as defined by clinically significant elevation of blood urea nitrogen (BUN) or creatinine or an estimated creatinine clearance of < 60 mL/min; AST and/or ALT > 5 times the upper limit of the normal range and/or a serum bilirubin > 2 times the upper limit of normal. 3. History of glaucoma. 4. History of kidney stones. 5. Concurrent participation in another alcohol treatment study or any study involving medications. 6. Female patients who are pregnant or lactating. 7. Topiramate use in the past week prior to study entry. 8. Use of medications for alcohol dependence (disulfiram, naltrexone, or acamprosate) within the past week. 9. Needing acute medical detoxification from alcohol based on a score of 12 or more on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD). 10. Subjects who are legally mandated to participate in an alcohol treatment program. 11. Subjects who have had a suicide attempt in the past 6 months or suicidal ideation, with intent, in the 30 days prior to enrollment. 12. Subjects who have previously been treated with topiramate for any reason and discontinued treatment due to an adverse event or due to a hypersensitivity reaction to topiramate. 13. Subjects with seizure disorders. 14. Subjects currently being treated with another anticonvulsant. 15. Subjects who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the topiramate package insert.

Locations and Contacts

Brooke A. Lasher, BA, Phone: 415/221-4810, Ext: 4954, Email: brooke.lasher@va.gov

San Francisco VA Medical Center, San Francisco, California 94121, United States; Recruiting
Additional Information

Starting date: November 2012
Last updated: June 8, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017